# Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence

Source: https://onco.cc/key-papers/paper-momen-roknabadi-oncrna-colorectal-clin-cancer-res-2025/  
OnCo record `paper-momen-roknabadi-oncrna-colorectal-clin-cancer-res-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exai Bio's study of tumour-specific small RNAs in blood for detecting colorectal cancer.

## Summary

In the independent validation set of 192, overall sensitivity was 89 per cent at 90 per cent specificity, with 80 per cent sensitivity for stage I.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Clinical Cancer Research
- Year: 2025
- DOI: 10.1158/1078-0432.ccr-25-0449
- Authors: Momen-Roknabadi A, Karimzadeh M, Chen NC, et al.
- Findings: Sensitivity 89% at 90% specificity; 80% for stage I.
- What it means: Cell-free orphan RNAs detect early colorectal cancer in a case-control setting.
- Caveats: Case-control; company authors.

## Sources

- Momen-Roknabadi et al., Clin Cancer Res 2025: https://doi.org/10.1158/1078-0432.ccr-25-0449
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40366744/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid RNA biopsy (cell-free, vesicle and platelet RNA)](https://onco.cc/technologies/liquid-rna-biopsy/)
- companies: [Exai Bio](https://onco.cc/companies/exai-bio/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-momen-roknabadi-oncrna-colorectal-clin-cancer-res-2025.json